155 related articles for article (PubMed ID: 19124357)
41. Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma.
Weinstein SF; Pearlman DS; Bronsky EA; Byrne A; Arledge T; Liddle R; Stahl E
Ann Allergy Asthma Immunol; 1998 Jul; 81(1):51-8. PubMed ID: 9690573
[TBL] [Abstract][Full Text] [Related]
42. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study.
Singh D; Zhu CQ; Sharma S; Church A; Kalberg CJ
Pulm Pharmacol Ther; 2015 Apr; 31():85-91. PubMed ID: 25197005
[TBL] [Abstract][Full Text] [Related]
43. The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD.
Hanania NA; Kalberg C; Yates J; Emmett A; Horstman D; Knobil K
Pulm Pharmacol Ther; 2005; 18(1):19-22. PubMed ID: 15607123
[TBL] [Abstract][Full Text] [Related]
44. Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year.
Donohue JF; Ganapathy V; Bollu V; Stensland MD; Nelson LM
Clin Ther; 2017 Jan; 39(1):66-74. PubMed ID: 28011247
[TBL] [Abstract][Full Text] [Related]
45. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial.
Donohue JF; Hanania NA; Fogarty C; Campbell SC; Rinehart M; Denis-Mize K
Ther Adv Respir Dis; 2008 Aug; 2(4):199-208. PubMed ID: 19124372
[TBL] [Abstract][Full Text] [Related]
46. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium.
van Noord JA; de Munck DR; Bantje TA; Hop WC; Akveld ML; Bommer AM
Eur Respir J; 2000 May; 15(5):878-85. PubMed ID: 10853852
[TBL] [Abstract][Full Text] [Related]
47. Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonists.
Chen YJ; Makin C; Bollu VK; Navaie M; Celli BR
J Med Econ; 2016; 19(1):11-20. PubMed ID: 26357881
[TBL] [Abstract][Full Text] [Related]
48. Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD.
Bollu V; Ernst FR; Karafilidis J; Rajagopalan K; Robinson SB; Braman SS
Int J Chron Obstruct Pulmon Dis; 2013; 8():631-9. PubMed ID: 24353413
[TBL] [Abstract][Full Text] [Related]
49. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD.
Donohue JF; Hanania NA; Make B; Miles MC; Mahler DA; Curry L; Tosiello R; Wheeler A; Tashkin DP
Chest; 2014 Dec; 146(6):1531-1542. PubMed ID: 25451347
[TBL] [Abstract][Full Text] [Related]
50. Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. SLMT02 Italian Study Group.
Di Lorenzo G; Morici G; Drago A; Pellitteri ME; Mansueto P; Melluso M; Norrito F; Squassante L; Fasolo A
Clin Ther; 1998; 20(6):1130-48. PubMed ID: 9916607
[TBL] [Abstract][Full Text] [Related]
51. Tiotropium is less likely to induce oxygen desaturation in stable COPD patients compared to long-acting beta2-agonists.
Santus P; Centanni S; Morelli N; Di Marco F; Verga M; Cazzola M
Respir Med; 2007 Aug; 101(8):1798-803. PubMed ID: 17399972
[TBL] [Abstract][Full Text] [Related]
52. An evaluation of inhaled bronchodilator therapy in patients hospitalized for non-life-threatening COPD exacerbations.
Woods JA; Usery JB; Self TH; Finch CK
South Med J; 2011 Nov; 104(11):742-5. PubMed ID: 22024782
[TBL] [Abstract][Full Text] [Related]
53. Clinical efficacy and safety of transdermal tulobuterol in the treatment of stable COPD: an open-label comparison with inhaled salmeterol.
Fukuchi Y; Nagai A; Seyama K; Nishimura M; Hirata K; Kubo K; Ichinose M; Aizawa H;
Treat Respir Med; 2005; 4(6):447-55. PubMed ID: 16336029
[TBL] [Abstract][Full Text] [Related]
54. Duration of salmeterol-induced bronchodilation in mechanically ventilated chronic obstructive pulmonary disease patients: a prospective clinical study.
Malliotakis P; Linardakis M; Gavriilidis G; Georgopoulos D
Crit Care; 2008; 12(6):R140. PubMed ID: 19014570
[TBL] [Abstract][Full Text] [Related]
55. [Onset of action of formoterol in patients with moderate to severe, partially reversible airflow obstruction assessed by bodyplethysmography].
Beier J; Beeh KM; Tröger K; Stenglein S; Bräutigam M; Buhl R; Schmidt EW
Pneumologie; 2002 Sep; 56(9):535-41. PubMed ID: 12215911
[TBL] [Abstract][Full Text] [Related]
56. Arformoterol tartrate in the treatment of COPD.
Cazzola M; Hanania NA; Matera MG
Expert Rev Respir Med; 2010 Apr; 4(2):155-62. PubMed ID: 20406080
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of nebulized flunisolide combined with salbutamol and ipratropium bromide in stable patients with moderate-to-severe chronic obstructive pulmonary disease.
Paggiaro PL; Vagaggini B; Di Franco A; Zingoni M; Fano M; Biraghi M
Respiration; 2006; 73(5):603-9. PubMed ID: 16293958
[TBL] [Abstract][Full Text] [Related]
58. Salmeterol improves fluid clearance from alveolar-capillary membrane in COPD patients: a pilot study.
Di Marco F; Guazzi M; Sferrazza Papa GF; Vicenzi M; Santus P; Busatto P; Piffer F; Blasi F; Centanni S
Pulm Pharmacol Ther; 2012 Feb; 25(1):119-23. PubMed ID: 22245487
[TBL] [Abstract][Full Text] [Related]
59. Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease.
Madaan A
Drugs Today (Barc); 2009 Jan; 45(1):3-9. PubMed ID: 19271027
[TBL] [Abstract][Full Text] [Related]
60. Salmeterol plus theophylline combination therapy in the treatment of COPD.
ZuWallack RL; Mahler DA; Reilly D; Church N; Emmett A; Rickard K; Knobil K
Chest; 2001 Jun; 119(6):1661-70. PubMed ID: 11399688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
